| Population 2015 |
68 million |
| |
| | | | | |
| Estimates of TB burden*, 2015 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
8.4 |
(6.9–10) |
12 |
(10–15) |
| Mortality (HIV+TB only) |
5.4 |
(3.3–8.1) |
8 |
(4.9–12) |
| Incidence (includes HIV+TB) |
117 |
(69–176) |
172 |
(102–259) |
| Incidence (HIV+TB only) |
15 |
(8–25) |
22 |
(12–37) |
| Incidence (MDR/RR-TB)** |
4.5 |
(2.9–6.2) |
6.6 |
(4.3–9.1) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2015 |
| |
0-14 years |
> 14 years |
Total |
| Females |
3.9 |
(2.1–5.6) |
32 |
(5.2–58) |
36 |
(7.3–64) |
| Males |
2.7 |
(1.6–3.9) |
78 |
(53–103) |
81 |
(55–107) |
| Total |
6.6 |
(4.1–9) |
110 |
(82–138) |
117 |
(69–176) |
| |
| | | | | |
| TB case notifications, 2015 |
|
| Total cases notified |
66 179 |
| Total new and relapse |
62 135 |
| - % tested with rapid diagnostics at time of diagnosis |
|
| - % with known HIV status |
98% |
| - % pulmonary |
84% |
| - % bacteriologically confirmed among pulmonary |
64% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2015 |
53% (35–89) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 |
0.12 (0.07–0.21) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2015 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
7 819 |
13% |
| - on antiretroviral therapy |
5 389 |
69% |
| |
| | | | | |
| Drug-resistant TB care, 2015 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
2 500
(2 000–3 000) |
| Estimated % of TB cases with MDR/RR-TB |
2.2% (1.5–2.9) |
24% (18–30) |
|
| % notified tested for rifampicin resistance |
10% |
30% |
7 970 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
|
| Laboratory-confirmed cases |
MDR/RR-TB: 466, XDR-TB: 5 |
| Patients started on treatment **** |
MDR/RR-TB: 506, XDR-TB: 5 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2014 |
80% |
58 774 |
| Previously treated cases, excluding relapse, registered in 2014 |
63% |
1 433 |
| HIV-positive TB cases, all types, registered in 2014 |
67% |
6 451 |
| MDR/RR-TB cases started on second-line treatment in 2013 |
|
|
| XDR-TB cases started on second-line treatment in 2013 |
|
|
| |
| | | | | |
| TB preventive treatment, 2015 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
|
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
|
| |
| | | | | |
| TB financing, 2016 |
|
| National TB budget (US$ millions) |
31 |
| Funding source: 36% domestic, 10% international, 54% unfunded |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed | | |
| | | | | |